News
OPNT
20.65
0.00%
0.00
UPDATE 1-US FDA approves Opiant's spray for reversing opioid-related overdoses
Reuters · 05/22/2023 21:39
US FDA approves Opiant's overdose reversal spray
Reuters · 05/22/2023 21:04
REUTERS NEWS SCHEDULE AT 10:00 a.m. GMT/6:00 a.m. ET
Reuters · 05/21/2023 10:01
UPDATE 1-Indivior lowers profit outlook on Opiant deal costs, boosts sales view
Reuters · 04/27/2023 11:49
Indivior lifts 2023 net revenue outlook, lowers profit forecast
Reuters · 04/27/2023 11:15
More
Webull provides a variety of real-time OPNT stock news. You can receive the latest news about Opiant Pharmaceuticals Inc through multiple platforms. This information may help you make smarter investment decisions.
About OPNT
Opiant Pharmaceuticals, Inc., is a specialty pharmaceutical company developing medicines for addictions and drug overdose. The Company has developed NARCAN (naloxone hydrochloride) Nasal Spray, a treatment to reverse opioid overdose. Its lead development product include OPNT003. The Company’s pipeline includes medicines in development for Opioid Overdose Reversal (OOR), Alcohol Use Disorder (AUD), Opioid Use Disorder (OUD), and Acute Cannabinoid Overdose (ACO). The Company also is focused on other treatment opportunities within the addiction and drug overdose field.